StatSure Announces Introduction of Company's Patented Barrel Format by Inverness Medical in U.S.

Share Name	Share Symbol	Market	Type
Chembio Diagnostics Inc	NASDAQ:CEMI	NASDAQ	Common Stock

Share Name

Share Symbol

Market

Type

Chembio Diagnostics Inc

NASDAQ:CEMI

NASDAQ

Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%	0.455	0.44	0.46				0	01:00:00

Price Change

% Change

Share Price

Bid Price

Offer Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

0.455

0.44

0.46

01:00:00

StatSure Announces Introduction of Company's Patented Barrel Format by Inverness Medical in U.S.

14/02/2007 5:05pm

PR Newswire (US)

Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart

From Jun 2019 to Jun 2024

Click Here for more Chembio Diagnostics Charts.

FRAMINGHAM, Mass., Feb. 14 /PRNewswire-FirstCall/ -- StatSure Diagnostic Corp. (OTC:SSUR) (BULLETIN BOARD: SSUR) is pleased to announce that it's long awaited and highly acclaimed patented barrel technology has finally been introduced to the U.S. by Inverness Medical (AMEX:IMA). In a deal signed in September 2006, Inverness became the exclusive distributor of StatSure's patented format for the HIV test worldwide. StatSure has no costs associated with the sale or manufacture of this product and receives payment for each test sold by Inverness. StatSure intends to build on Inverness recognition of the advantages of its unique and patented format, through the introduction in its format of a number of other infectious disease tests. The StatSure format is marketed by Inverness under the Inverness Clearview(R) brand. Detailed information on this product is available at http://invernessmedicalpd.com/poc/products/clr_hiv_complete.html Clearview COMPLETE HIV 1/2 is a rapid qualitative screening test for the detection of antibodies to HIV-1 and HIV-2 in human whole blood, serum and plasma. The test utilizes a single lateral flow test strip which displays results through visual observation of a control line (non-reactive result) and a test line (reactive result) within 15 minutes. The test is the safest and easiest to use blood test introduced to date and is manufactured for Inverness under license from StatSure by Chembio Diagnostic Systems (OTC:CEMI) (BULLETIN BOARD: CEMI) . The Clearview products have 15 minute times to detection and 24-month, room temperature shelf life from date of manufacture. Competitive advantages include product performance, safety, ease of use, shelf life, multiple sample types, and minimal sample size requirement using only 2 microliters of blood. (a pin drop) The StatSure format is unique in that there is no transfer of the sample to the test. The sample is absorbed directly into the test by capillary action with no exposure to sample as all blood is enclosed in barrel. The format is especially designed for home use. Inverness has the largest point of care marketing organization in the United States which supports a large distributor network. Inverness' launch brings important new rapid HIV testing options to the U.S. and coincides with the new CDC recommendations (http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm), StatSure's format together with Inverness marketing is positioned to capture a large portion of the growing market for rapid HIV tests. DATASOURCE: StatSure Diagnostic Corp. CONTACT: Investor Relations of StatSure Diagnostic Systems, Inc., +1-508-872-2625

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

CEMI Chembio Diagnostics Inc